Literature DB >> 20577894

Anti-tumour effects of xanthone derivatives and the possible mechanisms of action.

Quan-Guan Su1, Yan Liu, Yu-Chen Cai, Yue-Li Sun, Bo Wang, Li-Jian Xian.   

Abstract

To explore the potential anti-tumour activities of xanthone derivatives, 26 hydroxylxanthones and benzoxanthones and their structurally modified analogues were examined for potential cytotoxic activities against eight human cancer cell lines. Most of the xanthone derivatives exhibited a higher degree of cytotoxicity on HepG2 cells than on the other seven cancer cell lines. Compound 24 (1,3,7-Trihydroxy-12H-benzo[b] xanthen-12-one) showed the highest degree of cytotoxicity of the tested compounds against HepG2 cells and demonstrated good tumour specificity by exhibiting a much higher degree of cytotoxicity against HepG2 cells than against normal liver cells (L02). Several valuable structure-activity relationships were derived from the cytotoxicity data. In addition, we found that compound 24 could downregulate the expression of the Mcl-1 protein, induce changes in the mitochondrial membrane potential and induce apoptosis in HepG2 cells via the mitochondrial pathway. Compound 24 was also shown to inhibit topoisomerase (topo) II activity and downregulate the levels of both topo II mRNA and protein in HepG2 cells. The present results suggest that due to its potent cytotoxicity and good tumour selectivity, compound 24 may be exploited as a potential lead compound in the development of a new anti-tumour agent with specific activity against liver cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20577894     DOI: 10.1007/s10637-010-9468-5

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  27 in total

1.  Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC.

Authors:  S Shimizu; M Narita; Y Tsujimoto
Journal:  Nature       Date:  1999-06-03       Impact factor: 49.962

Review 2.  Life-or-death decisions by the Bcl-2 protein family.

Authors:  J M Adams; S Cory
Journal:  Trends Biochem Sci       Date:  2001-01       Impact factor: 13.807

3.  Treatment-related symptom clusters.

Authors:  Norissa Honea; Jeannine Brant; Susan L Beck
Journal:  Semin Oncol Nurs       Date:  2007-05       Impact factor: 2.315

Review 4.  Organelle-specific initiation of cell death pathways.

Authors:  K F Ferri; G Kroemer
Journal:  Nat Cell Biol       Date:  2001-11       Impact factor: 28.824

5.  Protective effect of Mangifera indica L. extract (Vimang) on the injury associated with hepatic ischaemia reperfusion.

Authors:  Gregorio Martínez Sánchez; María A Rodríguez H; Attilia Giuliani; Alberto J Núñez Sellés; Niurka Pons Rodríguez; Olga Sonia León Fernández; L Re
Journal:  Phytother Res       Date:  2003-03       Impact factor: 5.878

6.  Synthesis of xanthone derivatives with extended pi-systems as alpha-glucosidase inhibitors: insight into the probable binding mode.

Authors:  Yan Liu; Lin Ma; Wen-Hua Chen; Bo Wang; Zun-Le Xu
Journal:  Bioorg Med Chem       Date:  2007-02-16       Impact factor: 3.641

7.  EPOX inhibits angiogenesis by degradation of Mcl-1 through ERK inactivation.

Authors:  Hui-Lung Sun; An-Chi Tsai; Shiow-Lin Pan; Qingqing Ding; Hirohito Yamaguchi; Chun-Nan Lin; Mien-Chie Hung; Che-Ming Teng
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

8.  Synthesis, inhibitory activities, and QSAR study of xanthone derivatives as alpha-glucosidase inhibitors.

Authors:  Yan Liu; Zhuofeng Ke; Jianfang Cui; Wen-Hua Chen; Lin Ma; Bo Wang
Journal:  Bioorg Med Chem       Date:  2008-06-26       Impact factor: 3.641

9.  Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo.

Authors:  N Zamzami; P Marchetti; M Castedo; C Zanin; J L Vayssière; P X Petit; G Kroemer
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

Review 10.  Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.

Authors:  J F Kerr; A H Wyllie; A R Currie
Journal:  Br J Cancer       Date:  1972-08       Impact factor: 7.640

View more
  5 in total

1.  Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.

Authors:  Elirosa Minniti; Jo Ann W Byl; Laura Riccardi; Claudia Sissi; Michela Rosini; Marco De Vivo; Anna Minarini; Neil Osheroff
Journal:  Bioorg Med Chem Lett       Date:  2017-09-08       Impact factor: 2.823

2.  Synergistic Effect of 1,3,6-Trihydroxy-4,5,7-Trichloroxanthone in Combination with Doxorubicin on B-Cell Lymphoma Cells and Its Mechanism of Action Through Molecular Docking.

Authors:  Isnatin Miladiyah; Emmy Yuanita; Satyo Nuryadi; Jumina Jumina; Sofia Mubarika Haryana; Mustofa Mustofa
Journal:  Curr Ther Res Clin Exp       Date:  2020-01-30

3.  QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase IIα.

Authors:  Sarfaraz Alam; Feroz Khan
Journal:  Drug Des Devel Ther       Date:  2014-01-31       Impact factor: 4.162

4.  Biological activity, quantitative structure-activity relationship analysis, and molecular docking of xanthone derivatives as anticancer drugs.

Authors:  Isnatin Miladiyah; Jumina Jumina; Sofia Mubarika Haryana; Mustofa Mustofa
Journal:  Drug Des Devel Ther       Date:  2018-01-15       Impact factor: 4.162

5.  Contribution of reactive oxygen species to the anticancer activity of aminoalkanol derivatives of xanthone.

Authors:  Daniel Sypniewski; Natalia Szkaradek; Tomasz Loch; Anna M Waszkielewicz; Agnieszka Gunia-Krzyżak; Daria Matczyńska; Dagna Sołtysik; Henryk Marona; Ilona Bednarek
Journal:  Invest New Drugs       Date:  2017-11-08       Impact factor: 3.850

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.